Content Stats & Analytics for @psycspotlight

Psychedelic Spotlight
@psycspotlight

32,608 followers

2024 FDA APPROVAL ON THE HORIZON? MDMA is an effective psychedelic medicine to treat PTSD, confirms a new MAPS-sponsored study published today in Nature Medicine. In the MDMA-AT group, 45 of 52 (86.5%) participants were responders with a clinically meaningful improvement at 18 weeks after baseline. At the end of the study, 71.2% of participants in the MDMA-AT group (37 out of 52) no longer had symptoms that met the criteria for PTSD according to the DSM-5, while in the placebo with therapy group, this was the case for 47.6% (20 out of 42) of participants. Additionally, 46.2% of participants in the MDMA-AT group (24 out of 52) and 21.4% of participants in the placebo with therapy group (9 out of 42) met the criteria for remission from PTSD. The second phase 3 trial of MDMA-assisted therapy for PTSD produced similar results to the first trial, which found 67 percent participants receiving the combination of MDMA and therapy no longer qualified for a PTSD diagnosis, compared to 32 percent who underwent the same therapy with a placebo. 104 participants diagnosed with PTSD were randomly selected to receive either MDMA or a placebo, along with three preparatory sessions and nine integrative therapy sessions. Neither the clinician nor the participants were told which medication they were being given. According to Rick Doblin, the founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), the results put the illegal Schedule 1 drug on track to possibly be approved by the FDA as early as next year. Tap the link in bio to learn more. Follow ➡️ @psycspotlight Follow ➡️ @psycspotlight_2.0 #psychedelic #psychedelicresearch #news #breakingnews #FDA #2024 #mentalhealth #alternativehealth #ptsd